National Pension Service Purchases New Shares in Revvity, Inc. (NYSE:RVTY)

National Pension Service bought a new stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 213,512 shares of the company's stock, valued at approximately $23,339,000. National Pension Service owned 0.17% of Revvity as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. acquired a new position in shares of Revvity during the 3rd quarter valued at $1,579,487,000. Ceredex Value Advisors LLC bought a new stake in Revvity in the 4th quarter valued at about $108,353,000. Charles Schwab Investment Management Inc. bought a new position in Revvity in the fourth quarter worth approximately $80,818,000. Swiss National Bank acquired a new stake in Revvity in the fourth quarter valued at approximately $42,434,000. Finally, Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Revvity during the fourth quarter valued at approximately $33,568,000. Institutional investors own 86.65% of the company's stock.

Revvity Price Performance

NYSE:RVTY traded up $1.51 during midday trading on Thursday, hitting $104.34. The company had a trading volume of 399,914 shares, compared to its average volume of 835,973. The company has a market capitalization of $12.89 billion, a PE ratio of 86.23, a P/E/G ratio of 2.62 and a beta of 1.09. The company has a quick ratio of 1.92, a current ratio of 2.23 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a 52-week low of $79.50 and a 52-week high of $131.96. The stock's fifty day moving average price is $104.29 and its 200-day moving average price is $101.30.

Revvity (NYSE:RVTY - Get Free Report) last released its earnings results on Monday, April 29th. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.04. The company had revenue of $649.90 million during the quarter, compared to the consensus estimate of $646.83 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. Revvity's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.01 EPS. As a group, research analysts expect that Revvity, Inc. will post 4.66 earnings per share for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be issued a $0.07 dividend. The ex-dividend date is Friday, July 19th. This represents a $0.28 annualized dividend and a yield of 0.27%. Revvity's dividend payout ratio (DPR) is presently 23.14%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RVTY. Robert W. Baird lifted their target price on Revvity from $126.00 to $127.00 and gave the company an "outperform" rating in a research report on Tuesday, April 30th. Stifel Nicolaus increased their target price on shares of Revvity from $95.00 to $110.00 and gave the company a "hold" rating in a report on Friday, February 2nd. TD Cowen boosted their price target on shares of Revvity from $123.00 to $130.00 and gave the stock a "buy" rating in a report on Tuesday, April 30th. KeyCorp lifted their target price on shares of Revvity from $110.00 to $126.00 and gave the stock an "overweight" rating in a research report on Friday, February 2nd. Finally, UBS Group downgraded Revvity from a "buy" rating to a "neutral" rating and increased their price target for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $118.17.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.